2022
Reversibility of brain glucose kinetics in type 2 diabetes mellitus
Sanchez-Rangel E, Gunawan F, Jiang L, Savoye M, Dai F, Coppoli A, Rothman DL, Mason GF, Hwang JJ. Reversibility of brain glucose kinetics in type 2 diabetes mellitus. Diabetologia 2022, 65: 895-905. PMID: 35247067, PMCID: PMC8960594, DOI: 10.1007/s00125-022-05664-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood Glucose Self-MonitoringBrainDiabetes Mellitus, Type 2FemaleGlucoseGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsKineticsMaleMiddle AgedConceptsType 2 diabetesBrain glucose levelsGlucose levelsHyperglycaemic clampGlycaemic controlBrain glucoseUncontrolled type 2 diabetesType 2 diabetes mellitusConclusions/interpretationThese findingsAims/hypothesisWePlasma glucose levelsLinear mixed-effects regression modelsMixed-effects regression modelsContinuous glucose monitoringMinimal weight changeMagnitude of improvementAge 44.8MethodsEight individualsSD HbA1cDiabetes mellitusCerebral glucoseInterpretationThese findingsWeek interventionRegimen intensificationPost intervention
2017
Metformin: clinical use in type 2 diabetes
Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017, 60: 1586-1593. PMID: 28770321, DOI: 10.1007/s00125-017-4336-x.Peer-Reviewed Original ResearchConceptsGlucose-lowering effectType 2 diabetesModerate chronic kidney diseaseOral glucose-lowering medicationsNew glucose-lowering drugsType 2 diabetes mellitusOptimal initial therapyGlucose-lowering medicationsChronic kidney diseaseFirst-line treatmentGlucose-lowering drugsGood safety profilePrecise mechanismHepatic glucose productionMore robust evidenceFoundation therapyInitial therapyCardiovascular eventsInflammatory markersRenal dysfunctionDiabetes mellitusWeight neutralityKidney diseaseSafety profileGlucose production